Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Exir LLC currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This portfolio is handled by 1 distinct examiner, JIANJIAN ZHU, who is also the busiest examiner with 1 pending office action. The prosecution is localized within 1 distinct art unit.
The presence of only 1 pending office action across 1 distinct art unit indicates a very focused prosecution effort. JIANJIAN ZHU manages the entirety of the company's active matters, meaning the outcome of the current portfolio rests on a single examiner's interpretation of Biotechnology & Pharmaceuticals standards. This concentration simplifies the coordination of responses and legal arguments. For a practitioner, this data suggests that understanding the specific tendencies of JIANJIAN ZHU is the primary priority.
There are no other examiners or art units to consider, which reduces the need for broad-based prosecution strategies. The singular nature of the workload allows for a deep dive into the specific requirements of the one active application. This focused profile is typical for companies with a single active matter at the patent office, providing a clear path for administrative management.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 1 | 58.8% | +82.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707061 | COMPOSITIONS AND METHODS FOR USING INDIVIDUALIZED GENOME ASSEMBLIES AND INDUCED PLURIPOTENT STEM CELL LINES OF NONHUMAN PRIMATES FOR PRE-CLINICAL EVALUATION | ZHU, JIANJIAN | 29d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18707061 | COMPOSITIONS AND METHODS FOR USING INDIVIDUALIZED GENOME ASSEMBLIES AND INDUCED PLURIPOTENT STEM CELL LINES OF NONHUMAN PRIMATES FOR PRE-CLINICAL EVALUATION | ZHU, JIANJIAN | 29d overdue |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18707061 | COMPOSITIONS AND METHODS FOR USING INDIVIDUALIZED GENOME ASSEMBLIES AND INDUCED PLURIPOTENT STEM CELL LINES OF NONHUMAN PRIMATES FOR PRE-CLINICAL EVALUATION | ZHU, JIANJIAN | 1631 | §103§112 | Final Rejection | 29d overdue | Pending | May 02, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial